Management of Esophageal Stenosis Due to Histoplasma with Self-Expanding Metal Stents

Total Page:16

File Type:pdf, Size:1020Kb

Management of Esophageal Stenosis Due to Histoplasma with Self-Expanding Metal Stents Case report Management of Esophageal Stenosis Due to Histoplasma with Self-expanding Metal Stents René Marcelo Escobar P., MD,1 Mónica Restrepo J., MD.2 1 Specialist in Digestive Endoscopy and Abstract Gastrointestinal Surgery at the Hospital Universitario San Vicente in Medellin, Colombia Benign esophageal strictures are a common cause of medical consultation and gastroenterological endos- Email: [email protected] copy. Usually, given their non-neoplastic nature, they have been managed with recurrent endoscopic dilation 2 Second Year Resident in General Surgery at the which is uncomfortable for the patient and which generates high costs due repetition. In addition, there is Universidad de Antioquia in Medellin, Colombia Email: [email protected] always the risk of esophageal perforation at every session. The use of esophageal stents for management of benign esophageal strictures is becoming increasingly more common and is promising for various etiologies. ......................................... We present a case of a benign esophageal stricture secondary to infection with histoplasma capsulatum Received: 03-05-14 Accepted: 02-02-15 which was managed entirely with a completely covered metal stent. This led to complete resolution of the obstruction. Keywords Histoplasma capsulatum, benign esophageal stricture, esophageal prosthesis. INTRODUCTION CLINICAL CASE DESCRIPTION Esophageal infections by opportunistic pathogens have increa- The patient was a 24 year old man who lived in a rural area of sed in frequency due to the increased number of patients with the department of Antioquia in Colombia. He came to the some degree of immunosuppression. Candida albicans is the Hospital Universitario San Vicente Fundación in Medellín, most common, but other fungi reported to cause infections Colombia after two months of suffering from fatigue, weak- are Aspergillus, Histoplasma and Blastomyces. All of these ness, left hemiparesis, weight loss, night sweats, fever, loose should be considered in patients with esophageal infections stools, urinary incontinence and abdominal pain in the who have any degree of immunosuppression and in patients epigastrium. In the eight days prior to admission, he had who do not respond to antibiotic treatment. suffered from loss of appetite, whitish lesions in his mouth, Cases of esophageal strictures have been reported a sore throat, hyperpigmented lesions on his left arm and following fungal infections of the esophagus. These cases hypopigmented lesions on his legs. have usually been managed with serial endoscopic dilation He had consumed cannabinoids and smoked tobacco and/or surgery. The advent of esophageal stents has opened since the age of 14 and had had heterosexual relations with the possibility of avoiding the complications of serial dila- three partners without the use of condoms since he began tions while obtaining satisfactory results in the treatment of engaging in sexual activity. He had suffered head trauma malignant esophageal strictures. Nevertheless, convincing and a drug overdose two years previously. evidence of any similar great advantages of the use of stents Upon physical examination the patient was found to to treat benign strictures has not yet been demonstrated. be hemodynamically stable but had a fever, cachexia, and 77 © 2015 Asociaciones Colombianas de Gastroenterología, Endoscopia digestiva, Coloproctología y Hepatología lymphadenopathy of the neck, right axilla and popliteal capsulatum. Antiretroviral therapy and fluconazole were fossae. His oral cavity had whitish lesions compatible begun, but amphotericin B was substituted because of the with thrush. Widespread crackles could be heard throug- development of liver toxicity. hout his lungs. A neurological assessment showed him to After 15 days of treatment the patient began to suffer be disoriented and hypertonic with left arm spasms. He from dysphagia and a high fever, so another endoscopy was had hypertrophied muscles in all four limbs. Symmetrical performed (Figure 2). It found complete improvement of movements of his face showed decreased strength on the the lesions in the esophageal mucosa although a review of left side similar to decreased strength in his extremities. images taken during endoscopy seemed to show an esopha- He had rounded hyperpigmented lesions about 0.5 cm in geal stricture. diameter on his left arm and hand, ulcerated lesions on his The oral antifungal voriconazole was prescribed and penis, and flat anal warts. the patient was discharged but continued treatment as an Endoscopy (Figure 1) showed severe circumferential outpatient. Twenty days later he was readmitted because inflammation of the mucosa in the upper and middle third of drooling and increasing difficulty of swallowing to the of the esophagus. There were flat, friable pseudopolypoid point that he could barely swallow liquids. fibrin-covered ulcers that were three to six mm in diameter Another endoscopy (Figure 3) showed a marked and which bled easily. In the distal third of the esophagus decrease in the esophageal circumference to a diameter of there were cotton-like lesions which could not be washed five mm about twenty cm from the dental arch. The stric- off and which were compatible with Candida. Samples of ture appeared to be fibrous. It was impossible to advance these lesions were taken for pathological and microbiolo- the endoscope farther. gical examination. An esophagogram confirmed an esophageal stricture of The diagnosis of de novo AIDS with neurosyphilis and approximately 3cm in length without prestenotic dilation oral and esophageal candidiasis was made after testing (Figure 4). showed 67,400 copies of the virus and CD73 (+) CD4 (+) The patient was discharged with a supraglottic diet, T lymphocytes. Biopsies and cultures of from the esopha- antifungal therapy and an order for endoscopic dilation. gus and colon reported compromise due to Histoplasma He was readmitted six days later with severe dysphagia. Figure 1. Initial upper endoscopy. 78 Rev Col Gastroenterol / 30 (1) 2015 Case report Figure 2. Second upper endoscopy. Figure 3. Third upper endoscopy. Management of Esophageal Stenosis Due to Histoplasma with Self-expanding Metal Stents 79 Figure 4. Esophagogram. Another endoscopy (Figure 5) showed a concentric stric- The patient began to tolerate feeding by mouth, so the ture 19cm from the dental arch with a necrotic area on the feeding tube was removed. Antifungal and antiretroviral right esophageal wall and a large number of 2mm to 4mm treatment continued. nodes superimposed on an ulcerated mucosa. The esopha- Five months later another upper endoscopy (Figure 8) was gus was impassable at the stricture. performed. It showed the proximal edge of the fully expanded It was decided not to endoscopically dilate the esophagus. esophageal stent 17cm from the dental arch. Very little food Instead a gastrostomy was opened to ensure a proper oral debris had stuck to the inside wall. The endoscope could be path, and the evolution of the necrotic area in the esopha- advanced without any inconvenience through to o the distal gus was closely monitored. Twenty days later another esophagus which was observed to be normal. The prosthesis endoscopy was performed (Figure 6). It found a concentric was easily removed without complication. The endoscopic stricture of the esophagus that was about 3mm in diame- review showed the caliber of the esophagus to be uniform in ter. The mucosa was red and irritated, but there had been a its entirety without evidence of stricture. In the area that was complete resolution of the necrotic area. Under fluorosco- covered by the prosthesis the mucosa had thickened secon- pic guidance, dye was endoscopically injected into the area dary to the presence of the foreign body. No active viral or of the stricture for three cm on either side in order to better fungal infections were apparent. The esophagus was properly observe it. Three Savary-Gilliard dilators of 5 mm, 7 mm insufflated so there was no suspicion of perforation. and 9 mm and a neonatal endoscope were used to dilate the The patient continued to receive normal feeding by esophagus. The procedure went smoothly, and the stricture mouth and continued his antiretroviral and antifungal was opened without problems until the circumference of treatment which was scheduled to last for 12 months. the middle and distal thirds were both normal. The esopha- geal mucosa was also observed to be normal. Finally, an DISCUSSION 8cm x 16mm fully covered self-expanding metal esopha- geal stent was released (TecnoStent, Medellín, Colombia) As the number of immunocompromised patients has without complications (Figure 7). increased, so too has the incidence of opportunistic 80 Rev Col Gastroenterol / 30 (1) 2015 Case report Figure 5. Fourth upper endoscopy. Figure 6. Endoscopy: mechanical esophageal dilatation and insertion of prostheses. Management of Esophageal Stenosis Due to Histoplasma with Self-expanding Metal Stents 81 Figure 7. Fluoroscopy: mechanical esophageal dilatation and insertion of prostheses. Figure 8. Removal of Esophageal Stent. 82 Rev Col Gastroenterol / 30 (1) 2015 Case report esophageal infections, particularly Candida albicans, her- or biopsy results in a high percentage of positive identifi- pes simplex, cytomegalovirus and other fungal infections. cations (8). Nevertheless, sometimes it is impossible to Candidiasis accounts for the largest number of these cases. distinguish between normal flora and colonization and The increased numbers of immunocompromised
Recommended publications
  • Managing Athlete's Foot
    South African Family Practice 2018; 60(5):37-41 S Afr Fam Pract Open Access article distributed under the terms of the ISSN 2078-6190 EISSN 2078-6204 Creative Commons License [CC BY-NC-ND 4.0] © 2018 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0 REVIEW Managing athlete’s foot Nkatoko Freddy Makola,1 Nicholus Malesela Magongwa,1 Boikgantsho Matsaung,1 Gustav Schellack,2 Natalie Schellack3 1 Academic interns, School of Pharmacy, Sefako Makgatho Health Sciences University 2 Clinical research professional, pharmaceutical industry 3 Professor, School of Pharmacy, Sefako Makgatho Health Sciences University *Corresponding author, email: [email protected] Abstract This article is aimed at providing a succinct overview of the condition tinea pedis, commonly referred to as athlete’s foot. Tinea pedis is a very common fungal infection that affects a significantly large number of people globally. The presentation of tinea pedis can vary based on the different clinical forms of the condition. The symptoms of tinea pedis may range from asymptomatic, to mild- to-severe forms of pain, itchiness, difficulty walking and other debilitating symptoms. There is a range of precautionary measures available to prevent infection, and both oral and topical drugs can be used for treating tinea pedis. This article briefly highlights what athlete’s foot is, the different causes and how they present, the prevalence of the condition, the variety of diagnostic methods available, and the pharmacological and non-pharmacological management of the
    [Show full text]
  • Red-Brown Patches in the Groin
    DERMATOPATHOLOGY DIAGNOSIS Red-Brown Patches in the Groin Dong Chen, MD, PhD; Tammie C. Ferringer, MD Eligible for 1 MOC SA Credit From the ABD This Dermatopathology Diagnosis article in our print edition is eligible for 1 self-assessment credit for Maintenance of Certification from the American Board of Dermatology (ABD). After completing this activity, diplomates can visit the ABD website (http://www.abderm.org) to self-report the credits under the activity title “Cutis Dermatopathology Diagnosis.” You may report the credit after each activity is completed or after accumu- lating multiple credits. A 66-year-old man presented with reddish arciform patchescopy in the inguinal area. THE BEST DIAGNOSIS IS: a. candidiasis b. noterythrasma c. pitted keratolysis d. tinea cruris Doe. tinea versicolor H&E, original magnification ×600. PLEASE TURN TO PAGE 419 FOR THE DIAGNOSIS CUTIS Dr. Chen is from the Department of Pathology and Anatomical Sciences, University of Missouri, Columbia. Dr. Ferringer is from the Departments of Dermatology and Laboratory Medicine, Geisinger Medical Center, Danville, Pennsylvania. The authors report no conflict of interest. Correspondence: Dong Chen, MD, PhD, Department of Pathology and Anatomical Sciences, University of Missouri, One Hospital Dr, MA204, DC018.00, Columbia, MO 65212 ([email protected]). 416 I CUTIS® WWW.MDEDGE.COM/CUTIS Copyright Cutis 2018. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher. DERMATOPATHOLOGY DIAGNOSIS DISCUSSION THE DIAGNOSIS: Erythrasma rythrasma usually involves intertriginous areas surface (Figure 1) compared to dermatophyte hyphae that (eg, axillae, groin, inframammary area). Patients tend to be parallel to the surface.2 E present with well-demarcated, minimally scaly, red- Pitted keratolysis is a superficial bacterial infection brown patches.
    [Show full text]
  • Tinea Capitis 2014 L.C
    BJD GUIDELINES British Journal of Dermatology British Association of Dermatologists’ guidelines for the management of tinea capitis 2014 L.C. Fuller,1 R.C. Barton,2 M.F. Mohd Mustapa,3 L.E. Proudfoot,4 S.P. Punjabi5 and E.M. Higgins6 1Department of Dermatology, Chelsea & Westminster Hospital, Fulham Road, London SW10 9NH, U.K. 2Department of Microbiology, Leeds General Infirmary, Leeds LS1 3EX, U.K. 3British Association of Dermatologists, Willan House, 4 Fitzroy Square, London W1T 5HQ, U.K. 4St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust, St Thomas’ Hospital, Westminster Bridge Road, London SE1 7EH, U.K. 5Department of Dermatology, Hammersmith Hospital, 150 Du Cane Road, London W12 0HS, U.K. 6Department of Dermatology, King’s College Hospital, Denmark Hill, London SE5 9RS, U.K. 1.0 Purpose and scope Correspondence Claire Fuller. The overall objective of this guideline is to provide up-to- E-mail: [email protected] date, evidence-based recommendations for the management of tinea capitis. This document aims to update and expand Accepted for publication on the previous guidelines by (i) offering an appraisal of 8 June 2014 all relevant literature since January 1999, focusing on any key developments; (ii) addressing important, practical clini- Funding sources cal questions relating to the primary guideline objective, i.e. None. accurate diagnosis and identification of cases; suitable treat- ment to minimize duration of disease, discomfort and scar- Conflicts of interest ring; and limiting spread among other members of the L.C.F. has received sponsorship to attend conferences from Almirall, Janssen and LEO Pharma (nonspecific); has acted as a consultant for Alliance Pharma (nonspe- community; (iii) providing guideline recommendations and, cific); and has legal representation for L’Oreal U.K.
    [Show full text]
  • Detection of Histoplasma DNA from Tissue Blocks by a Specific
    Journal of Fungi Article Detection of Histoplasma DNA from Tissue Blocks by a Specific and a Broad-Range Real-Time PCR: Tools to Elucidate the Epidemiology of Histoplasmosis Dunja Wilmes 1,*, Ilka McCormick-Smith 1, Charlotte Lempp 2 , Ursula Mayer 2 , Arik Bernard Schulze 3 , Dirk Theegarten 4, Sylvia Hartmann 5 and Volker Rickerts 1 1 Reference Laboratory for Cryptococcosis and Uncommon Invasive Fungal Infections, Division for Mycotic and Parasitic Agents and Mycobacteria, Robert Koch Institute, 13353 Berlin, Germany; [email protected] (I.M.-S.); [email protected] (V.R.) 2 Vet Med Labor GmbH, Division of IDEXX Laboratories, 71636 Ludwigsburg, Germany; [email protected] (C.L.); [email protected] (U.M.) 3 Department of Medicine A, Hematology, Oncology and Pulmonary Medicine, University Hospital Muenster, 48149 Muenster, Germany; [email protected] 4 Institute of Pathology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany; [email protected] 5 Senckenberg Institute for Pathology, Johann Wolfgang Goethe University Frankfurt, 60323 Frankfurt am Main, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-30-187-542-862 Received: 10 November 2020; Accepted: 25 November 2020; Published: 27 November 2020 Abstract: Lack of sensitive diagnostic tests impairs the understanding of the epidemiology of histoplasmosis, a disease whose burden is estimated to be largely underrated. Broad-range PCRs have been applied to identify fungal agents from pathology blocks, but sensitivity is variable. In this study, we compared the results of a specific Histoplasma qPCR (H. qPCR) with the results of a broad-range qPCR (28S qPCR) on formalin-fixed, paraffin-embedded (FFPE) tissue specimens from patients with proven fungal infections (n = 67), histologically suggestive of histoplasmosis (n = 36) and other mycoses (n = 31).
    [Show full text]
  • Therapies for Common Cutaneous Fungal Infections
    MedicineToday 2014; 15(6): 35-47 PEER REVIEWED FEATURE 2 CPD POINTS Therapies for common cutaneous fungal infections KENG-EE THAI MB BS(Hons), BMedSci(Hons), FACD Key points A practical approach to the diagnosis and treatment of common fungal • Fungal infection should infections of the skin and hair is provided. Topical antifungal therapies always be in the differential are effective and usually used as first-line therapy, with oral antifungals diagnosis of any scaly rash. being saved for recalcitrant infections. Treatment should be for several • Topical antifungal agents are typically adequate treatment weeks at least. for simple tinea. • Oral antifungal therapy may inea and yeast infections are among the dermatophytoses (tinea) and yeast infections be required for extensive most common diagnoses found in general and their differential diagnoses and treatments disease, fungal folliculitis and practice and dermatology. Although are then discussed (Table). tinea involving the face, hair- antifungal therapies are effective in these bearing areas, palms and T infections, an accurate diagnosis is required to ANTIFUNGAL THERAPIES soles. avoid misuse of these or other topical agents. Topical antifungal preparations are the most • Tinea should be suspected if Furthermore, subsequent active prevention is commonly prescribed agents for dermatomy- there is unilateral hand just as important as the initial treatment of the coses, with systemic agents being used for dermatitis and rash on both fungal infection. complex, widespread tinea or when topical agents feet – ‘one hand and two feet’ This article provides a practical approach fail for tinea or yeast infections. The pharmacol- involvement. to antifungal therapy for common fungal infec- ogy of the systemic agents is discussed first here.
    [Show full text]
  • Yeast Infection Division of Disease Control What Do I Need to Know?
    Division of Disease Control What Do I Need To Know? Yeast Infection (Thrush, Diaper Rash, Vaginitis) What is a yeast infection? Yeast infections are caused by a fungus called Candida albicans. These infections can present in a variety of forms. Yeast infections in women can infect the vagina, called vaginitis. Thrush causes mouth infections in young infants and can also be a presenting sign of HIV infection in adults. Candida also may be the cause of many types of diaper rash in young children. Who is at risk for a yeast infection? Anyone can get a yeast infection. What are the symptoms of a yeast infection? Candidia diaper rash: The diaper area is red. The redness is worse in the creases. Redness is often bordered by red pimples. Rash may have a shiny appearance. Sores or cracking or oozing is present in severe cases. Thrush White patches appear on the inside of cheeks and gums and tongue. Thrush usually causes no other signs or symptoms. Vaginitis Vaginal irritation, intense itchiness and vaginal discharge. How soon do symptoms appear? Incubation period is unknown. How is a yeast infection spread? The fungus is present in the intestinal tract and mucous membranes of healthy people. A warm environment allows for growth and spread. Page 1 of 2 Last Updated: 01/2016 Person-to-person transmission may occur from a woman to her infant when the mother has a yeast infection in her vagina and in breastfeeding mothers whose babies with thrush infect the mothers’ nipples. When and for how long is a person able to spread the disease? A person can spread disease as long as the infection is present.
    [Show full text]
  • Yeast Infection (Candidiasis)
    PROVIDER YEAST INFECTION (CANDIDIASIS) Candida can normally be found on the skin and in the mouth, throat, intestinal tract, and vagina of healthy people. In children, yeast infections are commonly found in the mouth or throat (thrush) or the diaper area. CAUSE Candida albicans, a fungus. SYMPTOMS Thrush - White, slightly raised patches on the tongue or inside the cheek. Diaper Rash - Smooth, shiny "fire engine" red rash with a raised border. Children who suck their thumbs or fingers may occasionally develop Candida infections around their fingernails. Under certain conditions, such as during antibiotic use or when skin is damaged and exposed to excessive moisture, the balance of the normal, healthy skin germs is upset. Therefore, yeast that normally live on the skin can overgrow and cause yeast infections. Most of the time these infections heal quickly, but sometimes illness can occur in infants, persons with weakened immune systems, or those taking certain antibiotics. SPREAD Rarely, by contact with skin lesions and mouth secretions of infected persons or asymptomatic carriers. Most infants who have Candida got it from their mother during childbirth. According to the Centers for Disease Control and Prevention, outbreaks of thrush in childcare settings may be the result of increased use of antibiotics rather than newly acquired Candida infections. INCUBATION Variable. For thrush in infants, it usually takes 2 to 5 days. For others, yeast infections may occur while taking antibiotics or shortly after stopping the antibiotics. CONTAGIOUS Contagious while lesions are present. Most infections occur from yeast in the PERIOD person’s own body. DIAGNOSIS Recommend parents/guardians call their healthcare provider to identify the fungus.
    [Show full text]
  • Candidiasis (Yeast)
    Sexually Transmitted Diseases/Infections Candidiasis (Yeast) Candidiasis, commonly called a "yeast" infection, affects most females at least once during their lives. Candidiasis – also called Vulvovaginal Candidiasis, or VVC – is currently the second most common cause of vaginal infections, after bacterial vaginosis. Most cases (85%-90%) are caused by Candida albicans. Although most patients have no risk factors, frequent infections may be linked to diabetes, corticosteroids, repeated courses of antibiotics, pregnancy, or HIV disease. Typical symptoms of Candidiasis include pruritus, vaginal soreness, dyspareunia, external dysuria, and abnormal vaginal discharge. Ten to 20 percent of women harbor Candida sp. and other yeasts in the vagina. Candidiasis can occur concomitantly with STDs. Most healthy women with uncomplicated Candidiasis have no identifiable precipitating factors. A diagnosis of Candida vaginitis is suggested clinically by the presence of external dysuria and vulvar pruritus, pain, swelling, and redness. Signs include vulvar edema; fissures; excoriations; or thick, curdy vaginal discharge. The diagnosis can be made in a woman who has signs and symptoms of vaginitis when either 1) a wet preparation (saline, 10% KOH) or Gram stain of vaginal discharge demonstrates yeasts, hyphae, or pseudohyphae; or 2) a culture or other test yields a yeast species. For women with negative wet mounts who are symptomatic, vaginal cultures for Candida should be considered. Short-course topical formulations (i.e., single dose and regimens of 1 - 3 days) effectively treat uncomplicated VVC. The topically applied azole drugs are more effective than nystatin. Treatment with azoles results in relief of symptoms and negative cultures in 80 to 90 percent of patients who complete therapy.
    [Show full text]
  • Vulvovaginal Candidiasis: a Current Understanding and Burning Questions
    Journal of Fungi Review Vulvovaginal Candidiasis: A Current Understanding and Burning Questions Hubertine M. E. Willems 1, Salman S. Ahmed 2, Junyan Liu 1, Zhenbo Xu 1,2 and Brian M. Peters 1,* 1 Department of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, USA; [email protected] (H.M.E.W.); [email protected] (J.L.); [email protected] (Z.X.) 2 School of Food Science and Engineering, South China University of Technology, Guangzhou 510641, China; [email protected] * Correspondence: [email protected] Received: 22 January 2020; Accepted: 19 February 2020; Published: 25 February 2020 Abstract: Candida albicans, along with other closely related Candida species, are the primary causative agents of vulvovaginal candidiasis (VVC)—a multifactorial infectious disease of the lower female reproductive tract resulting in pathologic inflammation. Unlike other forms of candidiasis, VVC is a disease of immunocompetent and otherwise healthy women, most predominant during their child-bearing years. While VVC is non-lethal, its high global incidence and profound negative impact on quality-of-life necessitates further understanding of the host and fungal factors that drive disease pathogenesis. In this review, we cover the current state of our understanding of the epidemiology, host response, fungal pathogenicity mechanisms, impact of the microbiome, and novel approaches to treatment of this most prevalent human candidal infection. We also offer insight into the latest advancements in the VVC field and identify important questions that still remain. Keywords: vaginitis; vulvovaginal; Candida; vagina; VVC; fungal; candidiasis 1. Pathology and Epidemiology of Vulvovaginal Candidiasis Vulvovaginal candidiasis (VVC), is an exceedingly common mucosal infection of the lower female reproductive tract (FRT), caused mostly by the polymorphic opportunistic fungus Candida albicans.
    [Show full text]
  • Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients
    American Thoracic Society Documents An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients Andrew H. Limper, Kenneth S. Knox, George A. Sarosi, Neil M. Ampel, John E. Bennett, Antonino Catanzaro, Scott F. Davies, William E. Dismukes, Chadi A. Hage, Kieren A. Marr, Christopher H. Mody, John R. Perfect, and David A. Stevens, on behalf of the American Thoracic Society Fungal Working Group THIS OFFICIAL STATEMENT OF THE AMERICAN THORACIC SOCIETY (ATS) WAS APPROVED BY THE ATS BOARD OF DIRECTORS, MAY 2010 CONTENTS immune-compromised and critically ill patients, including crypto- coccosis, aspergillosis, candidiasis, and Pneumocystis pneumonia; Introduction and rare and emerging fungal infections. Methods Antifungal Agents: General Considerations Keywords: fungal pneumonia; amphotericin; triazole antifungal; Polyenes echinocandin Triazoles Echinocandins The incidence, diagnosis, and clinical severity of pulmonary Treatment of Fungal Infections fungal infections have dramatically increased in recent years in Histoplasmosis response to a number of factors. Growing numbers of immune- Sporotrichosis compromised patients with malignancy, hematologic disease, Blastomycosis and HIV, as well as those receiving immunosupressive drug Coccidioidomycosis regimens for the management of organ transplantation or Paracoccidioidomycosis autoimmune inflammatory conditions, have significantly con- Cryptococcosis tributed to an increase in the incidence of these infections. Aspergillosis Definitive
    [Show full text]
  • ECIL-6 Guidelines for the Treatment of Invasive Candidiasis, Aspergillosis
    GUIDELINE ARTICLE ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis Ferrata Storti EUROPEAN HEMATOLOGY Foundation in leukemia and hematopoietic stem cell ASSOCIATION transplant patients Frederic Tissot, 1 Samir Agrawal, 2 Livio Pagano, 3 Georgios Petrikkos, 4 Andreas H. Groll, 5 Anna Skiada, 6 Cornelia Lass-Flörl, 7 Thierry Calandra, 1 Claudio Viscoli 8 and Raoul Herbrecht 9 1Infectious Diseases Service, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland; 2Division of Haemato-Oncology, St Bartholomew's Hospital and Blizard Institute, Queen Mary University, London, UK; 3Hematology, Catholic University of Sacred Heart, Roma, Italy; 4School of Medicine, European University Cyprus, Engomi, Cyprus; 5Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology, University Children’s Hospital, Münster, Germany; 61st Department of Medicine, University of Athens, Greece; 7Division of Hygiene and Medical Microbiology, Medical University of Innsbruck, Austria; 8 University of Genova (DISSAL), Infectious Disease Division, IRCCS San Martino-IST, Haematologica 2017 Genova, Italy and 9Oncology and Hematology, Hôpitaux Universitaires de Strasbourg and Université de Strasbourg, France Volume 102(3):433-444 ABSTRACT he European Conference on Infections in Leukemia (ECIL) pro - vides recommendations for diagnostic strategies and prophylac - Ttic, pre-emptive or targeted therapy strategies for various types of infection in patients with hematologic malignancies or hematopoietic stem cell transplantation recipients. Meetings are held every two years since 2005 and evidence-based recommendations are elaborated after evaluation of the literature and discussion among specialists of nearly all Correspondence: European countries. In this manuscript, the ECIL group presents the [email protected] 2015-update of the recommendations for the targeted treatment of inva - sive candidiasis, aspergillosis and mucormycosis.
    [Show full text]
  • Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs August 2020
    Development considerations for Coccidioidomycosis Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs August 2020 David Angulo, MD Chief Medical Officer at SCYNEXIS Disclosures: employee and shareholder of SCYNEXIS, Inc Ibrexafungerp (SCY-078) Novel Glucan Synthase Inhibitor (GSI) Attributes / Development • In vitro and in vivo activity against: • Candida spp • Aspergillus spp • Pneumocystis spp • Coccidioides spp • Extensive tissue distribution (Vdss > 5 L/kg) Structurally distinct from other GSIs • In clinical development for: (echinocandins) • Invasive candidiasis (P2 study completed) • Vulvovaginal candidiasis (P3 studies completed) • Different enzyme-drug interaction → • Recurrent VVC (P3 study ongoing) lower impact of common FKS mutations • Invasive aspergillosis (P2 study ongoing) • Oral bioavailability • Candida auris infection (P3 ongoing) • Refractory invasive fungal diseases including coccidioidomycosis (P3 ongoing) 2 Products with labeled indications for the treatment of Coccidioidomycosis in the US • Fluconazole NO • Itraconazole NO • Amphotericin B deoxycholate YES • Ambisome NO • Posaconazole NO • Echinocandins NO IDSA 2016 guideline: No clinical studies exist to guide the optimal dose or duration of fluconazole or other antifungal therapy for persons with primary pulmonary coccidioidomycosis.1 1. Galgiani J, et al. IDSA Guideline - Coccidioidomycosis. Clin Infect Dis 2016 3 Complexities of coccidioidomycosis trials • The number of cases are limited ~150,000 cases a year but the majority do not receive antifungal treatment 15,611 cases reported in 20181 – Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever) – NIAID 2015-20182 – Conducted in 9 sites in Arizona and California – Planned for 1000 CAP in endemic regions - Enrolled 72 subjects and “Terminated for lack of feasibility” – Potential issues with the feasibility of the design 1. https://www.cdc.gov/fungal/diseases/coccidioidomycosis/statistics.html 2.
    [Show full text]